Inhibrx Reports Second Quarter 2025 Financial Results
SAN DIEGO, Aug. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2025. Following the complet...
What is the analyst consensus and target price revision, if any, following this earnings release?
Are there any risks or uncertainties disclosed in the filing that could affect future performance (e.g., litigation, regulatory delays)?
What is the outlook for the remaining INBRX product candidates and their potential impact on revenue growth?
26 days ago